ArticleMolecular and cellular biochemistry2018
GL261 glioma tumor cells respond to ATP with an intracellular calcium rise and glutamate release.
Article in Molecular and cellular biochemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- First cell-patterning of primary, patient-derived mesenchymal glioblastoma brain cancer cells on parylene-C/SiO2 substrates.PloS one · 2026Article
- Neurotransmitter-Mediated Signaling in Glioblastoma and Glial Tumors: Biology and Therapeutic Opportunities.Oncology research · 2026Review
- Single-Cell Transcriptomic Profiling of GL261 Glioblastoma Cells Reveals Gene Expression Signatures Underlying Tumorigenicity.Cellular and molecular neurobiology · 2025Article
- Expression and Functional Role of the P2X7 Receptor in Glioma Models and Tissues: A Systematic Review.Cancers · 2025Review
- Glioblastoma cell-derived exosomes induce cell death and oxidative stress in primary cultures of olfactory neurons. Role of redox stress.Molecular biology reports · 2023Article
- P2X7 receptor: the regulator of glioma tumor development and survival.Purinergic signalling · 2022Article
- Thioredoxin Reductase Inhibitors as Potential Antitumors: Mercury Compounds Efficacy in Glioma Cells.Frontiers in molecular biosciences · 2022Article
- Effects on Metabolism in Astrocytes Caused by cGAMP, Which Imitates the Initial Stage of Brain Metastasis.International journal of molecular sciences · 2021Article
- SOX1 Is a Backup Gene for Brain Neurons and Glioma Stem Cell Protection and Proliferation.Molecular neurobiology · 2021Review
- Mechanisms of Invasion in Glioblastoma: Extracellular Matrix, CaFrontiers in cellular neuroscience · 2021Review
- Role of Purinome, A Complex Signaling System, In Glioblastoma Aggressiveness.Frontiers in pharmacology · 2021Article
- Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma.Cancers · 2020Review
- Pathway analysis of glutamate-mediated, calcium-related signaling in glioma progression.Biochemical pharmacology · 2020Review
- Sphingosine-1-Phosphate in the Tumor Microenvironment: A Signaling Hub Regulating Cancer Hallmarks.Cells · 2020Review
- Cell Calcium Imaging as a Reliable Method to Study Neuron-Glial Circuits.Frontiers in neuroscience · 2020Review
- The P2X7 Receptor: Central Hub of Brain Diseases.Frontiers in molecular neuroscience · 2020Review
- Glutamate Receptors and Glioblastoma Multiforme: An Old "Route" for New Perspectives.International journal of molecular sciences · 2019Review
- Glioblastoma: Role of Mitochondria N-acetylserotonin/Melatonin Ratio in Mediating Effects of miR-451 and Aryl Hydrocarbon Receptor and in Coordinating Wider Biochemical Changes.International journal of tryptophan research : IJTR · 2019Review
- Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability.Cellular and molecular life sciences : CMLS · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma (GBM) is an aggressive brain cancer with an average survival rate of 15 months. The composition of the GBM tumor microenvironment-its pH, the presence of growth and immune factors, neurotransmitters, and gliotransmitters-plays an important role in GBM pathophysiology and facilitates tumor survival and growth. In particular, GBM tumor cells produce glutamate, which is toxic to healthy tissue and is associated with increased tumor invasion into adjacent brain regions. The conditions that lead to this excitotoxic release of glutamate are not completely understood. Previous studies have demonstrated that extracellular ATP is present at high levels in the tumor microenvironment, and that ATP stimulates the release of glutamate from astrocytes in culture. Here we examine the functional effects of extracellular ATP on the GL261 cell line, a model system for high-grade astrocytomas such as GBM. We show that treatment with ATP leads to an immediate, dose-dependent influx of calcium into the cell that is partially inhibited by an antagonist (o-ATP) of the ionotropic ATP receptor P2X7. In addition, GL261 cells respond to extracellular ATP with a dose-dependent release of glutamate. Consistent with other reports, we find that ATP is toxic to GL261 cells at high concentrations. Together, these results provide insight into the mechanisms responsible for glutamate production by tumor cells and inform future studies that will identify how the GBM tumor microenvironment facilitates tumor invasion into healthy areas of the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.